brain injury Archives - Sanford Burnham Prebys
Institute News

Meet neuroscientist Paloma Sánchez Pavón

AuthorMonica May
Date

October 7, 2020

Paloma’s research aims to protect premature babies from brain damage

Newborns have a new scientist in their corner: Paloma Sánchez Pavón, a graduate student in the lab of Jerold Chun, MD, PhD Paloma is working to find a medicine that could protect the still-developing brains of premature babies, which are incredibly delicate and prone to swelling. Called hydrocephalus, the condition is common—affecting one in 1,000 newborns—and repeated brain surgery is the only treatment.

We caught up with Paloma to learn more about what makes her tick, including why she decided to become a scientist and what she wishes people knew about research.

  • Did you always know you wanted to be a scientist? When you were a child, did you ever imagine you would be in the role you are today?
    I always knew I wanted to become a scientist, but I didn’t imagine I would be in the position I am today. Growing up, I was obsessed with the idea of becoming a marine biologist. I was fascinated by how much we didn’t know about the ocean. My plan was to move closer to the beach and enroll in a program that would allow me to learn more about it. Nevertheless, I soon realized that I was both mesmerized and terrified of the ocean (sharks, especially), and that I would never be able to spend enough time diving and exploring the water, which is what such a career would require. I was still passionate about biology and science in general, so I decided to study the most unknown (and equally unexplored) organ in the human body—the brain.
  • What do you study, and what is your greatest hope for your research?

    I study hydrocephalus, a condition that often affects premature infants. These newborns are extremely fragile and often accumulate fluid in their heads, which can cause brain damage or death. The only treatment is invasive brain surgery, required multiple times throughout individuals’ lives, to insert a shunt in their brains and drain the excess fluid so it is reabsorbed somewhere else in the body. This procedure is extremely uncomfortable for the patients and, like any other surgery, is associated with several risks that endanger their lives. I’m trying to understand the disease so we can find a better, less invasive treatment.

Paloma Sánchez Pavón at the beach in front of the ocean at sunset

When Paloma isn’t working in the lab, she can be found enjoying one of San Diego’s many beautiful beaches

  • What is one scientific question you wish you had an absolutely true answer to?
    To answer this question, I will step away from biology and turn to the universe. What is there beyond our galaxy? Will we be able to inhabit other planets? If we have so many things to still learn about the ocean and the brain, the universe is in a completely different category, with so many possibilities ahead of us.
  • What do you wish people knew about science?
    That it is fun. Experiments are about testing limits and going beyond what is known. I think that is really exciting. Also, science advances because we’re constantly asking new questions. Curiosity is what keeps this field in continuous evolution. And never be afraid to ask questions because science can be understood by everybody—it just needs to be explained well.
  • When you aren’t working in the lab, where can you be found? Where is your happy place?
    You will find me at the beach, walking along it or watching a sunset. One of the main reasons why I decided to move to San Diego is because I fell in love with its sunsets. You will also find me having brunch (my favorite American tradition) with my friends or enjoying a beer after work with them, especially around Encinitas or downtown San Diego.
  • What is the best career advice you have ever received?
    Never stop pushing the boundaries of knowledge. A curious mind is what keeps a scientist passionate about their job. Experiments usually don’t work the first time. You have to keep asking new questions and learning from your mistakes. Finishing a project takes time, but every day is unexpected and exciting because you don’t know what you’re going to find. That is the thrilling part about being a scientist.
  • What do you wish people knew about Sanford Burnham Prebys?
    What a great community Sanford Burnham Prebys is. I’ve never been in such a collaborative environment, where you work closely not only with students and postdocs, but also with faculty members. Everyone is always willing to help, whether that is lending reagents or advising about different techniques. As a student, this is what I value the most because it helps me develop as a scientist in an extremely enriching way.

Learn more about our Graduate School of Biomedical Sciences.

Institute News

SBP spin off company AivoCode receives funding to advance drugs to treat brain injuries

AuthorSusan Gammon
Date

June 22, 2017

Every year, over 10 million people worldwide injure their brain, and it’s the most common cause of death and disability in young people. There are currently no drugs available to limit the additional damage to the brain from swelling and inflammation after the injury or help repair the brain.

Novel technology developed in the lab of Erkki Ruoslahti, MD, PhD, distinguished professor at SBP, has led to spin off company called AivoCode that just received funding from the National Science Foundation to advance a new platform for site-specific delivery of drugs to treat acute brain injury.

The approach uses a peptide sequence of four amino acids, cysteine, alanine, glutamine and lysine (CAQK) that recognizes brain tissue. The CAQK peptide binds to the components of the meshwork surrounding brain cells called chondroitin sulfate proteoglycans. Amounts of these large, sugar-coated proteins increase following brain injury, and CAQK can carry drugs and nanoparticles to damaged areas in the brain.  The original proof-of-concept studies were performed on mouse models of acute brain injury and human brain tissue samples.

The technology may make it possible to use new types of drugs that would otherwise not reach their target in the brain. If the company is successful in bringing the technology to the clinic, it may improve the outcome for brain injury victims and provide significant healthcare savings.

 

 

 

 

 

Institute News

New technology could deliver drugs to brain injuries

AuthorJessica Moore
Date

June 28, 2016

A new study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) describes a technology that could lead to new therapeutics for traumatic brain injuries. The discovery, published in Nature Communications, provides a means of homing drugs or nanoparticles to injured areas of the brain.

“We have found a peptide sequence of four amino acids, cysteine, alanine, glutamine, and lysine (CAQK), that recognizes injured brain tissue,” said Erkki Ruoslahti, MD, PhD, distinguished professor in SBP’s NCI-Designated Cancer Center and senior author of the study. “This peptide could be used to deliver treatments that limit the extent of damage.”

About 2.5 million people in the US sustain traumatic brain injuries each year, usually resulting from car crashes, falls, and violence. While the initial injury cannot be repaired, the damaging effects of breaking open brain cells and blood vessels that ensue over the following hours and days can be minimized.

“Current interventions for acute brain injury are aimed at stabilizing the patient by reducing intracranial pressure and maintaining blood flow, but there are no approved drugs to stop the cascade of events that cause secondary injury,” said Aman Mann, PhD, postdoctoral researcher in Ruoslahti’s lab and co-first author of the study with Pablo Scodeller, PhD, another postdoc in the lab.

More than one hundred compounds are currently in preclinical tests to lessen brain damage following injury. These candidate drugs block the events that cause secondary damage, including inflammation, high levels of free radicals, over-excitation of neurons, and signaling that leads to cell death.

“Our goal was to find an alternative to directly injecting therapeutics into the brain, which is invasive and can add complications,” explained Ruoslahti. “Using this peptide to deliver drugs means they could be administered intravenously, but still reach the site of injury in sufficient quantities to have an effect.”

The CAQK peptide binds to components of the meshwork surrounding brain cells called chondroitin sulfate proteoglycans. Amounts of these large, sugar-decorated proteins increase following brain injury.

“Not only did we show that CAQK carries drug-sized molecules and nanoparticles to damaged areas in mouse models of acute brain injury, we also tested peptide binding to injured human brain samples and found the same selectivity,” added Mann.

“This peptide could also be used to create tools to identify brain injuries, particularly mild ones, by attaching the peptide to materials that can be detected by medical imaging devices,” Ruoslahti commented. “And, because the peptide can deliver nanoparticles that can be loaded with large molecules, it could enable enzyme or gene-silencing therapies.”

This platform technology has been licensed by a startup company, AivoCode, which was recently awarded a Small Business Innovation Research (SBIR) grant from the National Science Foundation for further development and commercialization.

Ruoslahti’s team and their collaborators are currently testing the applications of these findings using animal models of other central nervous system (CNS) injuries such as spinal cord injury and multiple sclerosis.

The paper is available online here.

 

Institute News

Research suggests new way to prevent HIV-associated brain injury

Authorsgammon
Date

December 5, 2014

For about 50 percent of HIV-1-infected people, things as simple as buttoning a shirt, remembering the alphabet, and handling money may become compromised by a disorder known as HIV-induced brain injury. The condition occurs when receptors and proteins in an HIV-infected immune system produce toxic substances that lead to brain- and nerve-cell death. There is currently no treatment available for the more than 600,000 affected individuals in the U.S. In a new study by Sanford-Burnham researchers, blocking CCR5—an HIV co-receptor—was found to protect against brain injury and impairment of learning and memory. The findings, reported in The Journal of Immunology, create a new approach to treating HIV-induced brain injury and may help our understanding of the potential involvement of CCR5 in other diseases of the brain. Continue reading “Research suggests new way to prevent HIV-associated brain injury”